Glaucoma therapy: preservative-free for all?

References

• BaudouinCLabbéALiangHPaulyABrignole-BaudouinFPreservatives in eyedrops: the good, the bad and the uglyProg Retin Eye Res201029431233420302969
   PubMed Web of Science ®Google Scholar
• MeloniMPaulyAServiBDVarletBLBaudouinCOccludin gene expression as an early in vitro sign for mild eye irritation assessmentToxicol In Vitro201024127628519729060
   PubMed Web of Science ®Google Scholar
• ActisAGRolleTOcular surface alterations and topical antiglaucomatous therapy: a reviewOpen Ophthalmol J20148677225317218
   PubMedGoogle Scholar
• Aguayo BonniardAYeungJYChanCCBirtCMOcular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK)Expert Opin Drug Metab Toxicol2016121112791289
   PubMed Web of Science ®Google Scholar
• FreemanDPKahookMYPreservatives in topical ophthalmic medications: historical and clinical perspectivesExpert Rev Ophthalmol2009415964
   Google Scholar
• LeungEWMedeirosFAWeinrebRNPrevalence of ocular surface disease in glaucoma patientsJ Glaucoma200817535035518703943
   PubMed Web of Science ®Google Scholar
• AnwarZWellikSRGalorAGlaucoma therapy and ocular surface disease: current literature and recommendationsCurr Opin Ophthalmol201324213614323542350
   PubMed Web of Science ®Google Scholar
• FechtnerRDGodfreyDGBudenzDStewartJAStewartWCJasekMCPrevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medicationsCornea201029661862120386433
   PubMed Web of Science ®Google Scholar
• BroadwayDCGriersonIO’BrienCHitchingsRAAdverse effects of topical antiglaucoma medication. II. The outcome of filtration surgeryArch Ophthalmol199411211144614547980134
   PubMedGoogle Scholar
• BaudouinCOcular surface and external filtration surgery: mutual relationshipsDev Ophthalmol201250647822517174
   PubMedGoogle Scholar
• MovahedanADjalilianARCataract surgery in the face of ocular surface diseaseCurr Opin Ophthalmol2012231687222081034
   PubMed Web of Science ®Google Scholar
• NordstromBLFriedmanDSMozaffariEQuigleyHAWalkerAMPersistence and adherence with topical glaucoma therapyAm J Ophthalmol2005140459860616226511
   PubMed Web of Science ®Google Scholar
• KastelanSTomicMMetez SoldoKSalopek-RabaticJHow ocular surface disease impacts the glaucoma treatment outcomeBiomed Res Int2013201369632824224176
   PubMed Web of Science ®Google Scholar
• Cohen CastelOKeinan-BokerLGeyerOMilmanUKarkabiKFactors associated with adherence to glaucoma pharmacotherapy in the primary care settingFam Pract201431445346124927725
   PubMed Web of Science ®Google Scholar
• BaudouinCBechetoilleABronAIntérêt de la mesure de la qualité de vie (QDV) et de l’observance thérapeutique chez les patients atteints de glaucome chronique à angle ouvert. [Relevance of quality of life and treatment compliance measurement in patients with chronic open-angle glaucoma]J Fr Ophtalmol2000231010571064 French11139707
   PubMed Web of Science ®Google Scholar
• RossiGCTinelliCPasinettiGMMilanoGBianchiPEDry eye syndrome-related quality of life in glaucoma patientsEur J Ophthalmol200919457257919551671
   PubMed Web of Science ®Google Scholar
• BatraRTailorRMohamedSOcular surface disease exacerbated glaucoma: optimizing the ocular surface improves intraocular pressure controlJ Glaucoma2014231566022828007
   PubMed Web of Science ®Google Scholar
• Newman-CaseyPABlachleyTLeePPHeislerMFarrisKBSteinJDPatterns of glaucoma medication adherence over four years of follow-upOphthalmology2015122102010202126319441
   PubMed Web of Science ®Google Scholar
• WilsonWSDuncanAJJayJLEffect of benzalkonium chloride on the stability of the precorneal tear film in rabbit and manBr J Ophthalmol197559116676691203224
   PubMed Web of Science ®Google Scholar
• ChibretHToxicité oculaire du benzalkonium. [Ocular toxicity of benzalkonium]Ann Pharm Fr2011692108115 French21440103
   PubMedGoogle Scholar
• HuangCChenWChenYLiuZToxicity research status of benzalkonium chloride on ocular surfaceZhonghua Yan Ke Za Zhi2014504303306 Chinese24931157
   PubMedGoogle Scholar
• BaudouinCDetrimental effect of preservatives in eyedrops: implications for the treatment of glaucomaActa Ophthalmol200886771672618537937
   PubMed Web of Science ®Google Scholar
• TresslerCSBeattyRLempMAPreservative use in topical glaucoma medicationsOcul Surf20119314015821791189
   PubMed Web of Science ®Google Scholar
• PisellaPJPouliquenPBaudouinCPrevalence of ocular symptoms and signs with preserved and preservative free glaucoma medicationBr J Ophthalmol200286441842311914211
   PubMed Web of Science ®Google Scholar
• JaenenNBaudouinCPouliquenPManniGFigueiredoAZeyenTOcular symptoms and signs with preserved and preservative-free glaucoma medicationsEur J Ophthalmol200717334134917534814
   PubMed Web of Science ®Google Scholar
• BronAChiambarettaFPouliquenPRigalDRoulandJFEfficacy and safety of substituting a twice-daily regimen of timolol with a single daily instillation of nonpreserved beta-blocker in patients with chronic glaucoma or ocular hypertensionJ Fr Ophtalmol200326766867413130253
   PubMed Web of Science ®Google Scholar
• RoulandJFEtude CARAT: acceptabilité d’un collyre bêtabloquant sans conservateur dans le traitement du glaucome. [Acceptability of preservative-free beta-blocker eye drops in the treatment of glaucoma]Réflexions Ophtalmologiques20111504346 French
   Google Scholar
• Van WentCBrasnuEHamardPBaudouinCLabbéAInfluence des pathologies de la surface oculaire sur le traitement du glaucome. [The influence of ocular surface diseases in the management of glaucoma]J Fr Ophtalmol2011344230237 French21439676
   PubMed Web of Science ®Google Scholar
• LevratFPisellaPJBaudouinCTolérance clinique des collyres antiglaucomateux conservés et non conservés. Résultats d’une enquête inédite en Europe. [Clinical tolerance of antiglaucoma eyedrops with and without a preservative. Results of an unpublished survey in Europe]J Fr Ophtalmol1999222186191 French10327349
   PubMed Web of Science ®Google Scholar
• CampagnaPMacriARolandoMChronic topical eye preservative-free beta-blocker therapy effect on the ocular surface in glaucomatous patientsActa Ophthalmol Scand (Suppl)199775S22453
   Google Scholar
• PisellaPJLalaEParierVRetentissement conjonctival des conservateurs: étude comparative de collyres bêta-bloquants conservés et non conservés chez des patients glaucomateux. [Effect of preservatives on the conjunctiva: a comparative study of beta-blocker eye drops with and without preservatives in glaucoma patients]J Fr Ophtalmol2003267675679 French13130254
   PubMed Web of Science ®Google Scholar
• PisellaPJDebbaschCHamardPConjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro studyInvest Ophthalmol Vis Sci20044551360136815111589
   PubMed Web of Science ®Google Scholar
• BursteinNLPreservative alteration of corneal permeability in humans and rabbitsInvest Ophthalmol Vis Sci19842512145314576511230
   PubMed Web of Science ®Google Scholar
• RoulandJFTraversoCEStalmansIT2345 Study GroupEfficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucomaBr J Ophthalmol201397219620023203707
   PubMed Web of Science ®Google Scholar
• FrezzottiPFogagnoloPHakaGIn vivo confocal microscopy of conjunctiva in preservative-free timolol 0.1% gel formulation therapy for glaucomaActa Ophthalmol2014922e133e14024020826
   PubMed Web of Science ®Google Scholar
• KatzGSpringsCLCravenERMontecchi-PalmerMOcular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprostClin Ophthalmol201041253126121151330
   PubMedGoogle Scholar
• IesterMTelaniSFrezzottiPOcular surface changes in glaucomatous patients treated with and without preservatives beta-blockersJ Ocul Pharmacol Ther201430647648124787056
   PubMed Web of Science ®Google Scholar
• UusitaloHEgorovEKaarnirantaKAstakhovYRopoABenefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trialsClin Ophthalmol20161044545427041987
   PubMed Web of Science ®Google Scholar
• ReardonGKotakSSchwartzGFObjective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic reviewPatient Prefer Adherence2011544146322003282
   PubMed Web of Science ®Google Scholar
• GurwitzJHGlynnRJMonaneMEverittDEGildenDSmithNAvornJTreatment for glaucoma: adherence by the elderlyAm J Public Health19938357117168484454
   PubMed Web of Science ®Google Scholar
• YeawJBennerJSWaltJGSianSSmithDBComparing adherence and persistence across 6 chronic medication classesJ Manag Care Pharm200915972874019954264
   PubMed Web of Science ®Google Scholar
• StewartWCDemosCMTurnerMKStewartJARisk factors for subject withdrawals in clinical trials evaluating glaucoma medicationsGraefes Arch Clin Exp Ophthalmol201024871007101220213475
   PubMed Web of Science ®Google Scholar
• NordmannJPAuzanneauNRicardSBerdeauxGVision related quality of life and topical glaucoma treatment side effectsHealth Qual Life Outcomes2003117514667241
   PubMedGoogle Scholar
• LoonSCJinJJin GohMThe relationship between quality of life and adherence to medication in glaucoma patients in SingaporeJ Glaucoma2015245e36e4224248002
   PubMed Web of Science ®Google Scholar
• OdbergTJakobsenJEHultgrenSJHalseideRThe impact of glaucoma on the quality of life of patients in Norway. I. Results from a self-administered questionnaireActa Ophthalmol Scand200179211612011284746
   PubMedGoogle Scholar
• BayerAWeilerWOeverhausUSkrotzkiFEStewartWCXplore Observation GroupTwo-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapiesJ Ocul Pharmacol Ther200420647047815684807
   PubMed Web of Science ®Google Scholar
• NordmannJPAkesbiJAméliorer l’adhérence au traitement des patients glaucomateux : le rôle du médecin. [Improve adherence in glaucoma patients: a doctor’s duty]J Fr Ophtalmol2011346403408 French21652110
   PubMed Web of Science ®Google Scholar
• Abegão PintoLVandewalleEGerlierLStalmansIImprovement in glaucoma patient quality of life by therapy switch to preservative-free timolol/dorzolamide fixed combinationOphthalmologica2014231316617124401549
   PubMed Web of Science ®Google Scholar
• LemijHGHoevenaarsJGvan der WindtCBaudouinCPatient satisfaction with glaucoma therapy: reality or myth?Clin Ophthalmol2015978579325999687
   PubMed Web of Science ®Google Scholar
• RüferFErbCEinflüsse des trockenen Auges auf die Glaukomdiagnostik. [Influence of dry eye syndrome on glaucoma diagnostic procedures]Ophthalmologe20121091110821086 German23179813
   PubMed Web of Science ®Google Scholar
• BroadwayDCChangLPTrabeculectomy, risk factors for failure and the preoperative state of the conjunctivaJ Glaucoma200110323724911442190
   PubMed Web of Science ®Google Scholar
• Romero-Díaz de LeónLMorales-LeónJELedesma-GilJNavasAConjunctival and corneal sensitivity in patients under topical antiglaucoma treatmentInt Ophthalmol201636329930326272426
   PubMed Web of Science ®Google Scholar
• Van WentCAlalwaniHBrasnuEÉvaluation de la sensibilité cornéenne chez les patients traités médicalement pour un glaucome ou une hypertonie oculaire. [Corneal sensitivity in patients treated medically for glaucoma or ocular hypertension]J Fr Ophtalmol20113410684690 French22093372
   PubMed Web of Science ®Google Scholar
• SarkarJChaudharySNamavariACorneal neurotoxicity due to topical benzalkonium chlorideInvest Ophthalmol Vis Sci20125341792180222410563
   PubMed Web of Science ®Google Scholar
• MartoneGFrezzottiPTosiGMAn in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphologyAm J Ophthalmol20091474725735.e119181302
   PubMed Web of Science ®Google Scholar
• LinZLiuXZhouTA mouse dry eye model induced by topical administration of benzalkonium chlorideMol Vis20111725726421283525
   PubMed Web of Science ®Google Scholar
• De Saint JeanMBrignoleFBringuierAFBauchetAFeldmannGBaudouinCEffects of benzalkonium chloride on growth and survival of Chang conjunctival cellsInvest Ophthalmol Vis Sci199940361963010067965
   PubMed Web of Science ®Google Scholar
• BuronNMicheauOCathelinSLafontainePOCreuzot-GarcherCSolaryEDifferential mechanisms of conjunctival cell death induction by ultraviolet irradiation and benzalkonium chlorideInvest Ophthalmol Vis Sci200647104221423017003409
   PubMed Web of Science ®Google Scholar
• HamardPBlondinCDebbaschCWarnetJMBaudouinCBrignoleFIn vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cellsGraefes Arch Clin Exp Ophthalmol2003241121037104314605906
   PubMed Web of Science ®Google Scholar
• YuALFuchshoferRKampikAWelge-LüssenUEffects of oxidative stress in trabecular meshwork cells are reduced by prostaglandin analoguesInvest Ophthalmol Vis Sci200849114872488018971427
   PubMed Web of Science ®Google Scholar
• SamplesJRBinderPSNayakSThe effect of epinephrine and benzalkonium chloride on cultured corneal endothelial and trabecular meshwork cellsExp Eye Res19894911122759185
   PubMed Web of Science ®Google Scholar
• SullivanDARochaEMAragonaPTFOS DEWS II Sex, Gender and Hormones ReportOcul Surf201715328433328736336
   PubMed Web of Science ®Google Scholar
• SharmaAHindmanHBAging: a predisposition to dry eyesJ Ophthalmol2014201478168325197560
   PubMed Web of Science ®Google Scholar
• SchaumbergDANicholsJJPapasEBTongLUchinoMNicholsKKThe international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGDInvest Ophthalmol Vis Sci20115241994200521450917
   PubMed Web of Science ®Google Scholar
• QuigleyHANumber of people with glaucoma worldwideBr J Ophthalmol19968053893938695555
   PubMed Web of Science ®Google Scholar
• RossiGCPasinettiGMScudellerLRaimondiMLanteriSBianchiPERisk factors to develop ocular surface disease in treated glaucoma or ocular hypertension patientsEur J Ophthalmol201323329630223335308
   PubMed Web of Science ®Google Scholar
• GhoshSO’HareFLamoureuxEVajpayeeRBCrowstonJGPrevalence of signs and symptoms of ocular surface disease in individuals treated and not treated with glaucoma medicationClin Experiment Ophthalmol201240767568122394358
   PubMed Web of Science ®Google Scholar
• MossSEKleinRKleinBEPrevalence of and risk factors for dry eye syndromeArch Ophthalmol200011891264126810980773
   PubMed Web of Science ®Google Scholar
• MossSEKleinRKleinBEIncidence of dry eye in an older populationArch Ophthalmol2004122336937315006852
   PubMed Web of Science ®Google Scholar
• EzuddinNSAlawaKAGalorATherapeutic strategies to treat dry eye in an aging populationDrugs Aging201532750551326123947
   PubMed Web of Science ®Google Scholar
• FoulksGNPharmacological management of dry eye in the elderly patientDrugs Aging200825210511818257598
   PubMed Web of Science ®Google Scholar
• DingJSullivanDAAging and dry eye diseaseExp Gerontol201247748349022569356
   PubMed Web of Science ®Google Scholar
• JohnsonATDrackAVKwitekAECannonRLStoneEMAlwardWLClinical features and linkage analysis of a family with autosomal dominant juvenile glaucomaOphthalmology199310045245298479711
   PubMed Web of Science ®Google Scholar
• HuangWPediatric glaucoma: a review of the basics2014 Available from: https://www.reviewofophthalmology.com/article/pediatric-glaucoma-a-review-of-the-basicsAccessed August 16, 2016
   Google Scholar
• PaschidesCAStefaniotouMPapageorgiouJSkourtisPPsilasKOcular surface and environmental changesActa Ophthalmol Scand199876174779541438
   PubMedGoogle Scholar
• WolkoffP“Healthy” eye in office-like environmentsEnviron Int20083481204121418499257
   PubMed Web of Science ®Google Scholar
• WolkoffPOcular discomfort by environmental and personal risk factors altering the precorneal tear filmToxicol Lett2010199320321220833234
   PubMed Web of Science ®Google Scholar
• WolkoffPNojgaardJKFranckCSkovPThe modern office environment desiccates the eyes?Indoor Air200616425826516842606
   PubMed Web of Science ®Google Scholar
• BlehmCVishnuSKhattakAMitraSYeeRWComputer vision syndrome: a reviewSurv Ophthalmol200550325326215850814
   PubMed Web of Science ®Google Scholar
• RosenfieldMComputer vision syndrome: a review of ocular causes and potential treatmentsOphthalmic Physiol Opt201131550251521480937
   PubMed Web of Science ®Google Scholar
• PimenidiMKPoluninGSSafonovaTNMeibomian gland disfunction in computer vision syndromeVestn Oftalmol201012664952 Russian
   Google Scholar
• FengaCAragonaPCacciolaAMeibomian gland dysfunction and ocular discomfort in video display terminal workersEye (Lond)2008221919517962818
   PubMed Web of Science ®Google Scholar
• MessmerEMThe pathophysiology, diagnosis, and treatment of dry eye diseaseDtsch Arztebl Int201511257181 quiz 225686388
   PubMed Web of Science ®Google Scholar
• BoimerCBirtCMPreservative exposure and surgical outcomes in glaucoma patients: the PESO studyJ Glaucoma201322973073523524856
   PubMed Web of Science ®Google Scholar
• ThiemeHvan der VeldenKKKonservierungsmittel aus Sicht der Glaukomchirurgie. [Preservatives from the perspective of glaucoma surgery]Ophthalmologe20121091110731076 German23179811
   PubMed Web of Science ®Google Scholar
• BaudouinCPisellaPJFillacierKOcular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studiesOphthalmology1999106355656310080214
   PubMed Web of Science ®Google Scholar
• BaudouinCMechanisms of failure in glaucoma filtering surgery: a consequence of antiglaucomatous drugs?Int J Clin Pharmacol Res199616129419001927
   PubMedGoogle Scholar
• BaudouinCSide effects of antiglaucomatous drugs on the ocular surfaceCurr Opin Ophthalmol1996728086
   PubMedGoogle Scholar
• TanLLMorganPCaiZQStraughanRAPrevalence of and risk factors for symptomatic dry eye disease in SingaporeClin Exp Optom2015981455325269444
   PubMed Web of Science ®Google Scholar
• PaulsenAJCruickshanksKJFischerMEDry eye in the beaver dam offspring study: prevalence, risk factors, and health-related quality of lifeAm J Ophthalmol2014157479980624388838
   PubMed Web of Science ®Google Scholar
• VersuraPCamposECMenopause and dry eye. A possible relationshipGynecol Endocrinol200520528929816019376
   PubMed Web of Science ®Google Scholar
• JinXLinZLiuYLinLZhuBHormone replacement therapy benefits meibomian gland dysfunction in perimenopausal womenMedicine (Baltimore)20169531e426827495030
   PubMed Web of Science ®Google Scholar
• AffinitoPDi Spiezio SardoADi CarloCEffects of hormone replacement therapy on ocular function in postmenopauseMenopause200310548248714501611
   PubMed Web of Science ®Google Scholar
• FengYFengGPengSLiHThe effect of hormone replacement therapy on dry eye syndrome evaluated with Schirmer test and break-up timeJ Ophthalmol2015201542030226664737
   PubMed Web of Science ®Google Scholar
• GuaschinoSGrimaldiESartoreAVisual function in menopause: the role of hormone replacement therapyMenopause2003101535712544677
   PubMed Web of Science ®Google Scholar
• PelitABagisTKayaselcukFDursunDAkovaYAydinPTear function tests and conjunctival impression cytology before and after hormone replacement therapy in postmenopausal womenEur J Ophthalmol200313433734212872789
   PubMed Web of Science ®Google Scholar
• GomesJAPAzarDTBaudouinCTFOS DEWS II Iatrogenic ReportOcul Surf201715351153828736341
   PubMed Web of Science ®Google Scholar
• MajumdarSHippalgaonkarKRepkaMAEffect of chitosan, benzalkonium chloride and ethylenediaminetetraacetic acid on permeation of acyclovir across isolated rabbit corneaInt J Pharm20083481–217517817897799
   PubMed Web of Science ®Google Scholar